EULAV Asset Management’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.7M Sell
14,618
-34,600
-70% -$19.4M 0.25% 98
2026
Q1
$27.7M Sell
49,218
-77,000
-61% -$49.4M 0.89% 37
2025
Q4
$85.4M Sell
126,218
-2
-0% -$1.36K 2.28% 9
2025
Q3
$80.6M Buy
126,220
+3
+0% +$1.82K 1.87% 13
2025
Q2
$67.7M Buy
126,217
+2
+0% +$956 1.59% 18
2025
Q1
$53M Buy
126,215
+3
+0% +$1.3K 1.31% 25
2024
Q4
$52.2M Hold
126,212
1.26% 25
2024
Q3
$63.8M Hold
126,212
1.55% 19
2024
Q2
$61.5M Buy
126,212
+6,197
+5% +$3.11M 1.66% 17
2024
Q1
$64.8M Buy
120,015
+13,903
+13% +$7.6M 1.78% 14
2023
Q4
$58.9M Hold
106,112
1.82% 14
2023
Q3
$46.4M Sell
106,112
-4,400
-4% -$2.19M 1.7% 10
2023
Q2
$55.5M Sell
110,512
-8,588
-7% -$4.12M 2.07% 6
2023
Q1
$59.6M Buy
119,100
+25,000
+27% +$12M 2.35% 5
2022
Q4
$38.4M Buy
94,100
+32,900
+54% +$12.8M 1.65% 14
2022
Q3
$19.9M Hold
61,200
0.88% 36
2022
Q2
$21.5M Sell
61,200
-19,800
-24% -$8.07M 0.89% 33
2022
Q1
$44.3M Sell
81,000
-4
-0% -$2.1K 1.32% 21
2021
Q4
$53.3M Sell
81,004
-13,200
-14% -$8.29M 1.35% 18
2021
Q3
$58.6M Hold
94,204
1.55% 13
2021
Q2
$59.5M Hold
94,204
1.57% 11
2021
Q1
$46.1M Sell
94,204
-4,998
-5% -$2.5M 1.24% 22
2020
Q4
$49.6M Sell
99,202
-9,998
-9% -$4.47M 1.3% 19
2020
Q3
$42.9M Hold
109,200
1.27% 20
2020
Q2
$36.1M Sell
109,200
-48,900
-31% -$14.2M 1.18% 22
2020
Q1
$38.3M Hold
158,100
1.53% 13
2019
Q4
$41.3M Sell
158,100
-16,100
-9% -$4.24M 1.42% 12
2019
Q3
$47.4M Sell
174,200
-2,300
-1% -$640K 1.75% 7
2019
Q2
$48.6M Sell
176,500
-1,200
-0.7% -$296K 1.82% 5
2019
Q1
$40M Hold
177,700
1.65% 7
2018
Q4
$33.1M Hold
177,700
1.65% 7
2018
Q3
$44.4M Sell
177,700
-5,300
-3% -$1.29M 1.9% 2
2018
Q2
$39.9M Sell
183,000
-20,300
-10% -$4.18M 1.83% 4
2018
Q1
$38.9M Sell
203,300
-27,200
-12% -$5.02M 1.86% 5
2017
Q4
$36M Sell
230,500
-6,900
-3% -$1.09M 1.7% 5
2017
Q3
$36.9M Hold
237,400
1.74% 4
2017
Q2
$38.3M Hold
237,400
1.88% 4
2017
Q1
$36.7M Hold
237,400
1.87% 3
2016
Q4
$27.8M Hold
237,400
1.5% 4
2016
Q3
$26.8M Hold
237,400
1.42% 5
2016
Q2
$22M Buy
237,400
+1,000
+0.4% +$85.9K 1.21% 8
2016
Q1
$18.5M Buy
236,400
+4,800
+2% +$346K 1.03% 14
2015
Q4
$16.9M Buy
231,600
+1,000
+0.4% +$71.3K 0.92% 25
2015
Q3
$17.1M Buy
230,600
+11,600
+5% +$831K 0.97% 16
2015
Q2
$14M Hold
219,000
0.74% 34
2015
Q1
$16.9M Buy
219,000
+2,000
+0.9% +$156K 0.87% 16
2014
Q4
$16.1M Buy
217,000
+46,400
+27% +$3.25M 0.87% 14
2014
Q3
$10.1M Hold
170,600
0.55% 61
2014
Q2
$11.4M Buy
170,600
+7,600
+5% +$483K 0.61% 49
2014
Q1
$9.89M Sell
163,000
-7,600
-4% -$453K 0.54% 65
2013
Q4
$9.07M Sell
170,600
-4,000
-2% -$211K 0.49% 70
2013
Q3
$8.7M Sell
174,600
-2,000
-1% -$96.1K 0.51% 68
2013
Q2
$7.93M Buy
+176,600
New +$7.72M 0.48% 68

Other funds holding IDXX

EULAV Asset Management's IDXX Position: Q2 2026 in Review

EULAV Asset Management reduced its Idexx Laboratories (IDXX) stake by 70% in Q2 2026, selling an estimated $19.4M and leaving 14,618 shares worth $7.7M. The position accounts for 0.25% of the portfolio, ranked #98.

EULAV Asset Management first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $85.4M in Q4 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • EULAV Asset Management held 14,618 shares of Idexx Laboratories worth $7.7M as of Q2 2026.
  • EULAV Asset Management sold 34,600 Idexx Laboratories shares in Q2 2026, an estimated $19.4M.
  • Idexx Laboratories made up 0.25% of EULAV Asset Management's portfolio in Q2 2026, its #98 holding.
  • EULAV Asset Management first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
  • EULAV Asset Management's Idexx Laboratories position peaked at $85.4M in Q4 2025.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on EULAV Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.